A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
Conditions
Healthy · Systemic Lupus Erythematosus · Rheumatoid Arthritis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Nucleus Network, Brisbane, Australia
Contact: Principal Investigator (Gloria Wong)Nucleus Network, Melbourne, Australia
Contact: Principal Investigator (Christina Catherine Chang)Peking University First Hospital, Beijing, China
Contact: Principal Investigator (Zhuoli Zhang)Peking University Third Hospital, Beijing, China
Contact: Principal Investigator (Rong MU)Xiangya Hospital of Central South University, Changsha, China
Contact: Principal Investigator (Hui LUO)Anhui Provincial Hospital, Hefei, China
Contact: Principal Investigator (Zhu CHEN)Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Contact: Principal Investigator (Shuang YE)The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
Contact: Principal Investigator (Li SUN)Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China
Contact: Principal Investigator (Qiubai LI)
Study leads
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Eli Lilly and Company